ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development Post author: Post published:November 13, 2023 Post category:uncategorized ATCC today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. You Might Also Like Diabetic retinal disease prevalence rises while severe cases decline March 3, 2025 Study paves the way for improving personalized treatment of patients with glioblastoma January 31, 2024 Researchers unveil groundbreaking approach to understanding brain activity December 9, 2024
Study paves the way for improving personalized treatment of patients with glioblastoma January 31, 2024